Stiripentol derivative and use thereof

Patent metadata

Field	Value
Publication number	US-12516043-B2
Application number	US-202118018792-A
Country	US
Kind code	B2
Filing date	Jul 30, 2021
Priority date	Jul 31, 2020
Publication date	Jan 6, 2026
Grant date	Jan 6, 2026

Abstract

The present invention provides a novel compound that can be used as a lactate dehydrogenase inhibitor or an active ingredient of a medicament such as an antiepileptic agent and an anti-cancer agent, and particularly, provides a novel compound excellent in metabolic stability. The novel compound according to the present invention is a compound represented by the following formula (1). In formula (1), R represents any substituent (for example, a monovalent substituent of an aromatic or non-aromatic 3 to 14-membered ring which may be unsubstituted or substituted and monocyclic or polycyclic), Ra, Rb, Rc, Rd, Re, Rf, Rg, Rh and Ri each represent a hydrogen atom or any substituent (for example, Ra to Ri are all hydrogen atoms, or Re, Rf, Rg, Rh and Ri are hydrogen atoms and at least one of Ra, Rb, Rc and Rd is any substituent).

First claim

The invention claimed is:

1 . A compound represented by the following formula (1):

wherein
R represents a monovalent substituent of an aromatic or non-aromatic 5 or 6-membered ring which may be unsubstituted or substituted with one to three substituents selected from the group consisting of a halogen atom, a hydroxy group, an oxo group, a sulfanyl group, a sulfo group, an amino group, an imino group, a nitro group, a formyl group, a carboxy group, a thiocarboxy group, a carbamoyl group, a thiocarbamoyl group and a cyano group; and
R a , R b , R c , R d , R e , R f , R g , R h and R i each independently represent a hydrogen atom or a halogen atom selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom and an iodine atom;
or a pharmaceutically acceptable salt or solvate thereof.

2 . The compound according to claim 1 , wherein the aromatic or non-aromatic 5 or 6-membered ring is a phenyl group, a pyridyl group, a thienyl group, a cyclohexenyl group or a cyclopentenyl group.

3 . The compound according to claim 1 , wherein R e , R f , R g , R h and R i are all hydrogen atoms.

4 . The compound according to claim 3 , wherein R a , R b , R c and R d are all hydrogen atoms.

5 . The compound according to claim 3 , wherein at least one of R a , R b , R c and R d is a halogen atom selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom and an iodine atom.

6 . A lactate dehydrogenase inhibitor comprising the compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof.

7 . A medicament comprising the compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof, as an active ingredient.

Assignees

• Nat Univ Corporation Okayama Univ

Inventors

• Inoue Tsuyoshi
• Sada Nagisa

Classifications

• C07D405/10

  linked by a carbon chain containing aromatic rings · CPC title

• C07D317/50

  with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring · CPC title

• A61P25/08 Primary

  Antiepileptics; Anticonvulsants · CPC title

• C07D409/10 Primary

  linked by a carbon chain containing aromatic rings · CPC title